Digoxin Starting Dose
For most adult patients, initiate digoxin at 0.125 to 0.25 mg once daily, with the lower dose (0.125 mg) specifically recommended for patients over 70 years of age, those with impaired renal function, or those with low lean body mass. 1, 2
Standard Dosing Algorithm
Initial Maintenance Dosing (Preferred Approach)
The FDA label and current guidelines support starting with maintenance dosing rather than loading doses for chronic heart failure management 3:
- Patients <70 years with normal renal function: Start 0.25 mg daily
- Patients ≥70 years OR impaired renal function OR low lean body mass: Start 0.125 mg daily
- Marked renal impairment: Start 0.0625 mg daily (or 0.125 mg every other day)
Steady-state concentrations will be achieved in 1-3 weeks depending on renal function, so clinical assessment should account for this delay. 3
Dose Adjustments
Doses may be increased every 2 weeks based on clinical response 3. Higher doses (0.375-0.50 mg daily) are rarely needed or used in modern heart failure management 1.
Critical Safety Considerations
Why Low Doses Are Mandatory
Retrospective analyses demonstrate a linear relationship between mortality and serum digoxin concentration, with significantly higher death risk at concentrations ≥1.2 ng/mL and ≥1.6 ng/mL. 1 This evidence fundamentally changed digoxin prescribing—the 2022 AHA/ACC/HFSA guidelines explicitly state that digoxin should be initiated at low doses because higher doses are "potentially detrimental" 1.
Recent data from 2025 confirms that digoxin toxicity can occur even at therapeutic serum concentrations, particularly in the setting of acute kidney injury, electrolyte disturbances, or drug interactions 4. This reinforces the need for conservative initial dosing.
Target Serum Concentrations
While the traditional therapeutic range was 0.8-2.0 ng/mL, current evidence supports targeting lower concentrations, ideally ≤0.9 ng/mL, particularly in heart failure patients 5, 6. The 2022 guidelines note that benefit in heart failure is controversial and digoxin should only be considered after optimization of guideline-directed medical therapy (GDMT) 1.
Special Populations
Elderly Patients (≥70 years)
Use 0.125 mg daily or every other day as the starting dose. 1, 2 Mean plasma concentrations increase significantly with age even when doses decrease, reflecting age-related changes in renal clearance and volume of distribution 7.
Renal Impairment
Dosing must be adjusted based on creatinine clearance (CrCl). The FDA label provides detailed tables, but the practical approach:
- CrCl 50-80 mL/min: 0.125 mg daily
- CrCl 30-50 mL/min: 0.125 mg daily (consider 0.0625 mg)
- CrCl <30 mL/min: 0.0625 mg daily 3
A 2022 Japanese population pharmacokinetic study found that with 0.125 mg daily, more than half of patients with CrCl <30 mL/min reached trough concentrations ≥0.9 ng/mL, supporting dose reduction to 0.0625 mg in this population 5.
Drug Interactions
Concurrent amiodarone use requires dose reduction. Population pharmacokinetic analysis identified amiodarone as a significant covariate affecting digoxin clearance 5. The same study recommended 0.0625 mg daily for patients on concurrent amiodarone, as 0.125 mg resulted in supra-therapeutic levels in more than half of patients 5.
Loading Doses: When and How
While maintenance dosing is preferred for chronic heart failure, rapid digitalization with loading doses may be appropriate in specific acute settings 3:
- Initial loading dose: 500-750 mcg (0.5-0.75 mg) produces detectable effect in 0.5-2 hours
- Additional doses: 125-375 mcg may be given at 6-8 hour intervals with careful clinical assessment
- Total loading dose: 750-1250 mcg (0.75-1.25 mg) for a 70 kg patient to achieve 8-12 mcg/kg peak body stores
However, loading doses are NOT recommended for routine initiation in chronic heart failure 8. The 2003 consensus guidelines explicitly state that "loading doses of digoxin are not necessary during initiation of therapy for patients with chronic heart failure" 8.
Common Pitfalls to Avoid
Overdosing elderly patients: The most common error is failing to reduce the dose in patients >70 years. Even 0.25 mg daily can lead to toxicity in this population 1.
Ignoring renal function: Digoxin is primarily renally cleared. Failure to adjust for renal impairment is a major cause of toxicity 3.
Using serum levels alone: Clinical context is paramount. Toxicity can occur at "therapeutic" levels, and efficacy may be present at lower-than-expected levels 3, 4.
Starting too high in modern practice: Historical dosing (often 0.25-0.375 mg) is no longer appropriate given mortality data at higher serum concentrations 1.
Contemporary Context
Digoxin's role has been substantially downgraded in modern heart failure management. The 2022 AHA/ACC/HFSA guidelines give it a Class 2b recommendation (may be considered) only for patients who remain symptomatic despite optimization of GDMT 1, 2. The benefit in patients on current four-pillar therapy (ACE inhibitors/ARBs/ARNI, beta-blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors) is unclear, as most trials preceded this regimen.
Recent 2025-2026 trials (DIGIT-HF with digitoxin and DECISION with low-dose digoxin) showed modest reductions in heart failure events without mortality benefit, confirming digoxin's limited but persistent role 9. The Dig-RHD trial (2026) demonstrated benefit specifically in rheumatic heart disease, a population with substantial global burden 9.